High Potency API Market

WuXi XDC, the antibody-drug conjugate (ADC) contract maker, grew 2025 revenue 46.7% to RMB 5.94 billion and ended the year with a USD 1.49 billion backlog, up 50.3%, its results of 23 March 2026 show; every ADC it builds carries a high potency payload. The high potency API market covers active pharmaceutical ingredients with occupational exposure limits of about 10 µg/m3 or lower, from cytotoxic cancer drugs and hormones to ADC payload-linkers. Douglas Insights sizes it at USD 25.5 billion in 2025, about 2,600 tonnes at an average USD 9,800 per kg, and at USD 55.7 billion in 2035, an 8.13% compound annual growth rate (CAGR). The study sits in our pharmaceutical manufacturing services coverage, beside the Biologics Outsourcing Market, Sterile Injectable Contract Manufacturing Market and Pharmaceutical Testing and Analytical Services Market reports; every figure follows the Douglas Insights research methodology.

Which high potency API class earns the most: cytotoxics, hormones or ADC payloads?

Cytotoxic oncology small molecules earn the most, 38.0% of 2025 high potency API revenue or about USD 9.68 billion, Douglas Insights estimates. ADC payloads and payload-linkers grow fastest, 15.0% a year to USD 11.3 billion by 2035.

Cytotoxics lead because most targeted and chemotherapy cancer drugs are potent enough to need closed handling. The US Food and Drug Administration’s drug centre approved 46 novel drugs in 2025, 20 of them first in class, and about 13 were for cancer by Douglas Insights count of its New Drug Therapy Approvals 2025 report. Cytotoxic revenue grows 7.3% a year to USD 19.6 billion, a Douglas Insights estimate.

Other potent small molecules, USD 8.66 billion, cover kinase inhibitors, immunology, central nervous system and cardiovascular drugs with low exposure limits, and grow 7.6%. Hormones and steroids, USD 4.33 billion, grow slowest at 4.6% because most are generic. ADC payload-linkers, USD 2.80 billion, are tiny by weight but sell at the highest prices per kg; Enhertu alone sold USD 2.78 billion in AstraZeneca’s 2025 accounts, up 40%, its results of 10 February 2026 show. Class values for 2035 sum to USD 55.7 billion, 0.08% above the headline.

Who makes high potency APIs: drug makers in-house or contract manufacturers?

Merchant and contract manufacturers supply 53.0% of 2025 high potency API revenue, about USD 13.5 billion, Douglas Insights estimates, and grow 9.3% a year; captive production by innovator drug makers supplies 47.0% and grows 6.7%.

Outsourcing leads because containment suites cost tens of millions of dollars and many biotech owners of potent drugs have no plants. Lonza’s Advanced Synthesis unit, which covers small molecules and bioconjugates, grew 2025 sales 22.4% to CHF 1.61 billion at a 41.8% margin, its full-year report of 28 January 2026 shows. Large drug makers keep some potent chemistry in-house, which is why Eli Lilly is building a USD 5 billion ADC and bioconjugate site in Goochland, Virginia, its release of 16 September 2025 states. Route values sum to USD 55.8 billion in 2035, 0.12% above the headline.

What drives high potency API demand: ADC launches, oncology pipelines or contract capacity?

High potency API revenue rises 8.13% a year in our base case: volume grows 5.6% a year, from about 2,600 tonnes to about 4,480 tonnes, and average price rises 2.4%. Four drivers add 6.8 points of volume; restraints remove 1.2.

ADC and oncology approvals: 2.6 points

New approvals are the largest driver, worth 2.6 points. The FDA approved datopotamab deruxtecan (Datroway), a TROP2 ADC, for HR-positive, HER2-negative breast cancer on 17 January 2025 and gave it accelerated approval in EGFR-mutated lung cancer on 23 June 2025. AbbVie won accelerated approval for Emrelis (telisotuzumab vedotin), a c-Met ADC, on 14 May 2025 and for Decnupaz (pivekimab sunirine), a CD123 ADC with a DNA-alkylating payload, on 27 May 2026. Douglas Insights estimates each new ADC adds 5 kg to 40 kg of payload-linker demand a year at peak.

Scale-up of launched ADCs: 1.7 points

Growth of drugs already on the market adds 1.7 points. AstraZeneca’s oncology sales rose 14% to USD 25.6 billion in 2025, with Enhertu at USD 2.78 billion, up 40%, and Datroway at USD 40 million in its first year, its results of 10 February 2026 show. Daiichi Sankyo booked JPY 698.4 billion of Enhertu product sales in the year to March 2026, its results of 11 May 2026 show. Gilead agreed to buy Tubulis for USD 3.15 billion upfront and up to USD 1.85 billion in milestones on 7 April 2026.

Contract capacity build-out: 1.3 points

New containment capacity adds 1.3 points. Lonza is expanding high potency payload-linker production at Visp for operation in 2028, its release of 30 June 2026 states, and will add 3 bioconjugation suites of up to 3,000 L there from 2028, its advisory of 29 October 2026 shows. Veranova is spending more than USD 50 million at Devens, Massachusetts, including 2 high potency suites rated to occupational exposure band (OEB) 6, its release of 16 July 2026 states. Cambrex is investing USD 120 million at Charles City, Iowa, a site that handles highly potent APIs, its release of 22 October 2025 shows.

Onshoring and supply-chain shifts: 1.2 points

The last 1.2 points come from drug makers moving potent chemistry closer to their markets. Johnson & Johnson raised its US investment to more than USD 55 billion over four years, including a Wilson, North Carolina plant for cancer medicines, its release of 21 March 2025 states, and Lilly has committed more than USD 50 billion of US capital since 2020, with 3 of 4 new sites for APIs, its release of 26 February 2025 shows. Summed, 2.6 + 1.7 + 1.3 + 1.2 = 6.8 points, a Douglas Insights estimate.

What holds high potency API growth back: containment bottlenecks, generic prices or worker safety rules?

Three restraints remove 1.2 points a year from high potency API volume growth: scarce containment capacity takes 0.5 points, generic price erosion 0.4 points and tighter worker-exposure rules 0.3 points.

Containment is the heaviest drag because a new OEB 5 or OEB 6 suite takes three to four years to design, build and qualify, a Douglas Insights estimate, and capacity announced in 2025 and 2026 mostly opens in 2027 and 2028. Piramal Pharma Solutions opened its commercial ADC payload-linker suite at Riverview, Michigan only in May 2026, a year after announcing a USD 90 million two-site US programme, its press releases show. Sterling Pharma Solutions’ new Deeside suite, which handles molecules with exposure limits down to 10 ng/m3, doubles its ADC capacity only from late 2026, its release of 5 October 2026 states.

Generic erosion takes 0.4 points as older cytotoxics and hormones lose patents and Indian and Chinese suppliers cut prices, a Douglas Insights estimate. Worker-safety rules take 0.3 points: the European Commission adopted a non-binding indicative list of hazardous medicinal products on 18 February 2025 under Directive 2004/37/EC, its release of 25 February 2025 states, and the US National Institute for Occupational Safety and Health (NIOSH) added 25 drugs to its hazardous drugs list on 19 December 2024, raising handling costs for smaller makers.

Which region uses the most high potency APIs, and where does demand grow fastest?

North America uses the most high potency APIs, USD 9.94 billion or 39.0% of 2025 revenue, because it buys the most new cancer drugs. Asia Pacific grows fastest, 10.4% a year to USD 17.1 billion by 2035.

North America leads on demand for patented potent drugs and is pulling production home. AstraZeneca plans USD 50 billion of US investment by 2030, its release of 21 July 2025 states, and Lonza agreed on 3 November 2026 to buy five US contract sites from Merck KGaA, including high potency payload-linker plants in Wisconsin, expecting about CHF 250 million of sales in 2028, its release shows. North American revenue grows 7.6% a year to USD 20.7 billion.

Europe, USD 7.39 billion, grows 7.1% on Swiss, Italian, French and British plants; Axplora began more than EUR 100 million of 2025 investments and an ADC payload expansion at Le Mans, its release of 7 October 2025 states. Asia Pacific, USD 6.37 billion, grows 10.4% on Chinese ADC contract work and Indian incentives: India’s production-linked incentive scheme for bulk drugs, with an outlay of INR 6,940 crore, had drawn INR 4,763.34 crore of investment by September 2025, the Press Information Bureau said on 2 December 2025. Latin America, USD 1.02 billion, grows 7.4%, and the Middle East and Africa, USD 0.76 billion, 8.0%. Regional values sum to USD 27.6 billion in 2026 and USD 56.2 billion in 2035, 0.92% above the headline.

Which companies lead high potency API supply?

Lonza and WuXi XDC lead contract supply of high potency payloads, Douglas Insights estimates, followed by Siegfried, Piramal, Cambrex, Veranova, Sterling and Axplora; the top five hold about 25% of merchant revenue.

Lonza grew first-half 2026 sales 16.0% at constant currency to CHF 3.37 billion, with Advanced Synthesis up 27.7% at a 48.1% margin, and raised its 2026 margin guidance to 33% to 34%, its results of 22 July 2026 show. WuXi XDC grew first-half revenue 37.0% to RMB 3.70 billion, lifted its backlog 50.4% to USD 2.00 billion, ran 328 integrated projects and plans capital spending of nearly RMB 8 billion for 2026 to 2030, its interim results of 24 August 2026 show.

Mid-sized chemistry specialists compete on containment and speed. Siegfried’s 2025 net sales rose 4.3% in local currencies to CHF 1.33 billion at a 23.5% core margin, its release of 20 February 2026 shows. Piramal’s Grangemouth site in Scotland delivered its 1,500th ADC batch in March 2026, its press releases show.

Captive makers remain large buyers and producers: Lilly’s Goochland site will make ADC drug substance and drug product in-house, and big oncology sponsors keep early-phase potent chemistry in their own kilo labs, a Douglas Insights estimate. Douglas Insights estimates more than 150 sites worldwide hold OEB 5 or higher containment, and about half sit with contract makers.

How much does a kilogram of high potency API cost, from hormones to ADC payloads?

A kilogram of high potency API costs an average USD 9,800 in 2025, Douglas Insights estimates, from about USD 500 for a generic steroid to USD 1 million or more for an ADC payload-linker made in grams.

The average hides a steep price ladder. Douglas Insights puts generic hormones and steroids at USD 500 to USD 5,000 per kg, generic cytotoxics at USD 3,000 to USD 30,000, patented potent small molecules at USD 20,000 to USD 200,000 and ADC payload-linkers at USD 200,000 to more than USD 2 million per kg. Hormones make up about 55% of tonnage but about 17% of revenue, a Douglas Insights estimate.

Average price rises 2.4% a year in the base case, to about USD 12,400 per kg in 2035, because the mix moves toward ADC payloads and new patented molecules even as generic prices fall. Containment drives the premium: Sterling spent about USD 3 million on a single isolator for handling compounds below 1 ng/m3 at Germantown, Tennessee, its release of 30 May 2024 states, and Douglas Insights estimates a contract maker charges 30% to 60% more per kg for OEB 5 work than for standard APIs.

Tariffs add a new cost layer. A US proclamation of 2 April 2026 under Section 232 sets a 100% tariff on patented drugs and their ingredients, 15% for the EU, Japan, Korea and Switzerland, and 0% for companies with pricing and onshoring agreements, while generic APIs are exempt “at this time”, the White House fact sheet states. Douglas Insights treats the effect as a shift of production to the US rather than a change in price.

What if ADCs disappoint or accelerate: how large is the high potency API market in 2035?

The high potency API market ends 2035 between USD 45.9 billion and USD 66.8 billion across our three cases, around a base of USD 55.7 billion. ADC launch success and containment capacity set most of the spread.

In the slower case fewer ADCs reach approval, generic erosion speeds up and new suites open late, taking 1.2 points off volume and 0.8 points off price. In the faster case ADCs move into earlier lines of breast and lung cancer and bispecific ADCs reach the market by 2030, adding 1.2 points of volume and 0.7 points of price. One extra point of yearly revenue growth adds about USD 5.37 billion to 2035 revenue, a Douglas Insights estimate.

Live signals sit slightly above the base case. WuXi XDC’s 50.4% backlog growth, Lonza’s 27.7% Advanced Synthesis growth and the Lonza purchase of Merck KGaA’s payload-linker sites point up. Siegfried’s 4.3% growth and generic price pressure point down. Our 5.6% volume rate weighs fast ADC growth against flat demand for older potent generics.

Which rules shape high potency API production, from worker exposure limits to BIOSECURE?

Three rule sets shape high potency API production: EU worker protection law under Directive (EU) 2022/431, European Medicines Agency (EMA) exposure limits for shared plants, and US rules such as BIOSECURE and Section 232 tariffs.

The worker layer matters most for plant design. Directive (EU) 2022/431 brought hazardous medicinal products into the EU carcinogens, mutagens and reprotoxic substances rules, with a transposition deadline of 5 April 2024, its text on EUR-Lex sets out, and the Commission’s indicative list, Communication C/2025/1150, was published on 20 February 2025. The EMA guideline on health-based exposure limits, EMA/CHMP/CVMP/SWP/169430/2012, still governs whether a potent product may share a plant, its guideline page shows.

The US security layer moves contracts. The BIOSECURE Act became law as Section 851 of the fiscal 2026 National Defense Authorization Act, signed on 18 December 2025, with a list of biotechnology companies of concern due by December 2026 and a five-year grandfather period for existing contracts, Arnold & Porter’s summary states. Douglas Insights expects US sponsors to dual-source potent payloads outside China from 2027, which supports Western contract makers.

Douglas Exclusive: the Potent Capacity Gap Index

The Potent Capacity Gap Index is a Douglas Insights model built from 12 inputs: 8 company releases and results and 4 regulator or government releases, listed below. It compares new high potency demand with new contained capacity each year.

The finding, a Douglas Insights estimate: demand for OEB 5 and higher payload capacity rises about 14% a year to 2028 while contained capacity rises about 10%, so the gap widens until 2028, then closes as Lonza, Veranova, Piramal and Lilly capacity opens. On the index, the gap stands at 1.18 in 2026, meaning 18% more demand than comfortable capacity, and falls to about 1.02 in 2029.

The index changes how to read the market. While the gap is above 1.10, contract makers hold pricing power and margins such as Lonza’s 48.1% in Advanced Synthesis persist; once it falls toward 1.0, price growth slows toward 1.5% a year. Douglas Insights therefore holds the price leg at 2.4% on average, higher before 2029 and lower after.

How does the methodology turn 2,600 tonnes into USD 25.5 billion?

Our methodology multiplies about 2,600 tonnes of high potency API made in 2025 by an average USD 9,800 per kg to reach USD 25.5 billion, then grows volume 5.6% and price 2.4% a year.

The model covers 4 API classes, 2 supply routes and 5 regions, using 61 data points, 25 sourced and 36 modelled. Volume comes from drug sales, dose and yield for potent drugs; prices come from company filings and Douglas Insights price ladders by class. Arithmetic: 2,600 tonnes x USD 9,800 per kg = USD 25.5 billion; USD 25.5 billion x (1.056 x 1.024)^10 = USD 55.7 billion. Volume reaches about 4,480 tonnes in 2035.

Two cross-checks agree. First, Lonza’s Advanced Synthesis and WuXi XDC together reported about USD 2.8 billion of 2025 revenue, of which Douglas Insights attributes about USD 1.4 billion to high potency work, about 10% of merchant revenue, consistent with a fragmented supply base. Second, our ADC payload value of USD 2.80 billion equals about 14% to 19% of the roughly USD 15 billion to USD 20 billion of 2025 ADC drug sales by Douglas Insights estimate, a plausible share for the most expensive input in a conjugate. Currency conversions use Douglas Insights assumptions of USD 1.24 per Swiss franc, RMB 7.10 and JPY 150 per dollar. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. WuXi XDC Cayman via HKEX WuXi XDC 2025 annual results announcement (2026)
2. US Food and Drug Administration New Drug Therapy Approvals 2025 (2026)
3. Lonza Group via SGX Lonza full-year results 2025 report (2026)
4. Eli Lilly and Company Lilly plans USD 5 billion Virginia facility (2025)
5. US Food and Drug Administration FDA approves datopotamab deruxtecan for HR-positive, HER2-negative breast cancer (2025)
6. US Food and Drug Administration FDA grants accelerated approval to datopotamab deruxtecan in EGFR-mutated NSCLC (2025)
7. AbbVie US FDA approves Emrelis (2025)
8. AbbVie US FDA approves Decnupaz (2026)
9. AstraZeneca Full-year and Q4 2025 results presentation (2026)
10. Daiichi Sankyo FY2025 financial results presentation (2026)
11. Gilead Sciences Gilead to acquire Tubulis (2026)
12. Lonza Group Lonza expands HPAPI payload-linker capacity in Visp (2026)
13. Lonza Group Lonza bioconjugation expansion in Visp (2026)
14. Veranova Inside Veranova HPAPI and ADC expansion (2026)
15. Cambrex via PR Newswire Cambrex USD 120 million Charles City expansion (2025)
16. Johnson & Johnson Johnson & Johnson increases US investment to more than USD 55 billion (2025)
17. Eli Lilly and Company Lilly plans to more than double US manufacturing investment (2025)
18. Piramal Pharma Solutions Press releases (2026)
19. Sterling Pharma Solutions Sterling expands ADC manufacturing capacity (2026)
20. European Commission Hazardous medicinal products: Commission communication (2025)
21. CDC NIOSH NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (2024)
22. AstraZeneca AstraZeneca plans to invest USD 50 billion in the US (2025)
23. Lonza Group Lonza to acquire US CDMO sites from Merck KGaA (2026)
24. Axplora Axplora investments exceeding EUR 100 million in 2025 (2025)
25. Press Information Bureau, Government of India PLI scheme for bulk drugs progress (2025)
26. Lonza Group Lonza half-year 2026 results (2026)
27. WuXi XDC Cayman via HKEX WuXi XDC 2026 interim results (2026)
28. Siegfried Holding Siegfried full-year 2025 results (2026)
29. Sterling Pharma Solutions Sterling expands HPAPI capabilities in Germantown (2024)
30. The White House Fact sheet: Section 232 tariffs on patented pharmaceutical products (2026)
31. EUR-Lex Directive (EU) 2022/431 (2022)
32. EUR-Lex Communication C/2025/1150: indicative list of hazardous medicinal products (2025)
33. European Medicines Agency Guideline on health-based exposure limits for shared facilities (2014)
34. Arnold & Porter The BIOSECURE Act becomes law (2025)

What counts in the high potency API study, and what is excluded?

The high potency API study counts active pharmaceutical ingredients with occupational exposure limits of about 10 µg/m3 or lower, made in-house or by contract makers worldwide, at manufacturer value. Finished dosage forms, antibodies, biologic drug substance and equipment are excluded.

The study splits revenue by 4 API classes, 2 supply routes and 5 regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Antibody production appears in our Biologics Outsourcing Market report, fill-finish in the Sterile Injectable Contract Manufacturing Market report and analytical work in the Pharmaceutical Testing and Analytical Services Market report.